anti human cd59 fitc (Miltenyi Biotec)
Miltenyi Biotec is a verified supplier 
Miltenyi Biotec manufactures this product 
93
Structured Review
Miltenyi Biotec
anti human cd59 fitc
Anti Human Cd59 Fitc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti human cd59 fitc/product/Miltenyi Biotec
Average 93 stars, based on 4 article reviews
Anti Human Cd59 Fitc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti human cd59 fitc/product/Miltenyi Biotec
Average 93 stars, based on 4 article reviews
anti human cd59 fitc - by Bioz Stars,
2026-03
93/100 stars
Images
1) Product Images from "Identification of CD320, SLC44A1 and TNFRSF13B as potential novel therapeutic targets for CAR T-cell therapy in multiple myeloma"
Article Title: Identification of CD320, SLC44A1 and TNFRSF13B as potential novel therapeutic targets for CAR T-cell therapy in multiple myeloma
Journal: Frontiers in Medicine
doi: 10.3389/fmed.2025.1737919
Figure Legend Snippet: Gene expression and cytogenetic clusters in MM. (A) Violin plots showing gene expression levels for TNFRSF13B , CD59 , FCGR2B , SLC44A1 , and CD320 in HD, MGUS, SMM, MM, RRMM. Statistical comparisons were conducted using the Kruskal–Wallis test for all pairwise contrasts. (B) Heatmap of the pseudobulk expression profiles showing normalized expression levels for eight putative proxy markers of cytogenetic aberrations across 54 MM patients. (C) Box plots illustrating the differential expression of TNFRSF13B , CD59 , FCGR2B , SLC44A1 , and CD320 across the four cytogenetic patient clusters. Statistical significance was evaluated using two-sided t -tests for all pairwise comparisons p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), p < 0.0001 (****).
Techniques Used: Gene Expression, Expressing, Quantitative Proteomics
Figure Legend Snippet: Kaplan–Meier survival curves showing the prognostic relevance of mRNA expression levels for CD59, SLC44A1, FCGR2B, TNFRSF13B, and CD320 genes. Cell populations with high expression of each gene are shown in blue, while populations with low expression of the same mRNA are shown in red. Reference datasets (GSE, GEO Series) are indicated at the top of each panel. Prognostic significance was assessed using the Cox proportional hazards model (95% confidence interval CI) and log-rank test, with p < 0.05 considered statistically significant.
Techniques Used: Expressing
Figure Legend Snippet: Histogram plots showing the cell surface expression of CD59, CD92, CD267, and CD320 molecules on different MM cell lines, including AMO-1, OPM-2, RPMI8226, U-266, and H929 as measured by flow cytometry analysis using fluorochrome-conjugated antibodies in triplicate experiments. Each panel represents the distribution of expression levels for the indicated marker, allowing comparison of protein abundance across the different cell lines compared to unstained control (in blue).
Techniques Used: Expressing, Flow Cytometry, Marker, Comparison, Quantitative Proteomics, Control
Figure Legend Snippet: Histogram plots showing the cell surface expression of CD59, CD92, CD267, and CD320 molecules on malignant plasma cells (PCs) from eight bone marrow samples of newly diagnosed, untreated MM patients as measured by flow cytometry analysis using fluorochrome-conjugated antibodies in triplicate experiments. Each panel represents the distribution of expression levels for the indicated marker across the eight MM patients samples, allowing comparison of protein abundance compared to unstained control (in blue).
Techniques Used: Expressing, Clinical Proteomics, Flow Cytometry, Marker, Comparison, Quantitative Proteomics, Control
